-
Mashup Score: 0Late-Breaking Study Data: BIOTRONIK’s Orsiro DES Outperforms Other Ultrathin Strut Drug-Eluting Stent - 9 month(s) ago
July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study investigators, Dr. Hyo-Soo Kim presented the results of a stent level analysis comparing two ultrathin strut drug-eluting stents (DES): Orsiro and Coroflex ISAR. The post-hoc comparison revealed significant differences in efficacy. HOST-IDEA is a large scale, multicenter, all-comers…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2"Very" very late stent thrombosis: acute myocardial infarction from drug-eluting stent thrombosis more than 5 years after implantation - PubMed - 11 month(s) ago
A serious long-term complication of drug-eluting stent (DES) implantation is the occurrence of very late stent thrombosis (VLST) beyond 1 year after implantation. While VLST has been observed as late as 3 to 5 years following the initial procedure, it remains unknown whether DES thrombosis is a fini …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
@gonzaeperez @SIAC_cardio @edurontoFF @SABOURETCardio @mmamas1973 @DFCapodanno @jpcostabel @jjamaro @javierguetta67 @Drroxmehran This is rare with new gen #DES. We reported a series of ST >5 years out which we labeled “very very late ST”. These were 1st gen DES and every one was off all antiplatelets and/or was smoking. Need to know this here & image as stent looks undersized. https://t.co/CVhW3pFJGY
-
-
Mashup Score: 0EuroPCR - 11 month(s) ago
EuroPCR is the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and a world-leading course in interventional cardiovascular medicine. The event attracts more than 11,000 participants. Learn more about this conference at www.pcronline.com.
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @ElixirMed #Latebreaking #clinical data presented at #EuroPCR23 demonstrated Elixir Medical’s #DynamX #Bioadaptor restores vessel motion and function with better effectiveness at 12 months compared to a leading drug-eluting #stent (#DES): https://t.co/0cAPGhTY7o
-
-
Mashup Score: 1Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial - 1 year(s) ago
AbstractAims. The best interventional strategy for the treatment of drug-eluting stent (DES) in-stent restenosis (ISR) is still unclear and no data from randomi
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Read more in EHJ! https://t.co/IdBBmUWXrU #DEB #DES #restenosis #PCI #EHJ #cardiotwitter @ESC_Journals @escardio https://t.co/WtKFdjUbbP
-
-
Mashup Score: 2Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis - 1 year(s) ago
AbstractAims. Optimal endovascular management of intermittent claudication (IC) remains disputed. This systematic review and meta-analysis compares efficacy and
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: check this meta-analysis in #EHJ! https://t.co/Wwrn88nVWo #claudication #endovascular #revascularization #DCB #DES #atherectomy #cardiotwitter @escardio @ESC_Journals https://t.co/inRnwCq2x3
-
-
Mashup Score: 1
Background: A clear patency benefit of a drug-eluting stent (DES) over bare metal stents (BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been definitively demonst
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet-
#DES for #PAD ? https://t.co/wpaKttpo2R
-
-
Mashup Score: 0Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation: Results From the PTRG-DES Consortium - 1 year(s) ago
Abstract Background The long-term prognostic implication of platelet reactivity after percutaneous coronary intervention (PCI) is not clearly known. Objectives The impacts of platelet reactivity fr…
Categories: Expert Picks, Latest HeadlinesTweet-
In this large-scale East Asian cohort treated w/ #DES w/ long-term clinical follow-up, high on-treatment platelet reactivity was significantly associated with the occurrence of #MACCE, all-cause death, and NACE at 5 years after #PCI. https://t.co/kVpJSyBHYj #JACCINT https://t.co/pOcGChR6nB
-
-
Mashup Score: 2Bioresorbable vascular scaffolds versus conventional drug-eluting stents across time: a meta-analysis of randomised controlled trials - 2 year(s) ago
Background Bioresorbable vascular scaffolds (BVS) were designed to reduce the rate of late adverse events observed in conventional drug-eluting stents (DES) by dissolving once they have restored lasting patency. Objectives Compare the safety and efficacy of BVS versus DES in patients receiving percutaneous coronary intervention for coronary artery disease across a complete range of randomised…
Source: Open HeartCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Bioresorbable vascular scaffolds #BVS vs. conventional drug-eluting stents #DES across time: A #metaanalysis of RCTs @banerjeep https://t.co/XyDVI7XNMi https://t.co/AjEPC6Zv3E
-
-
Mashup Score: 0Cordis to acquire MedAlliance, known for its drug-eluting balloons, in deal that could surpass $1B - 2 year(s) ago
Cordis has agreed to acquire MedAlliance, a Switzerland-based healthcare technology company focused on drug-eluting balloons, for an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all. Cordis pursued this deal due to its…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Cordis acquires MedAlliance, known for its drug-eluting balloon technology, in deal that could surpass $1B @cordis #cardiology #interventionalcardiology #cardiotwitter #PCI #DES https://t.co/UYLXF1HHss
-
-
Mashup Score: 0Drug-Eluting Stents Versus Conventional Endovascular Therapies in Symptomatic Infrapopliteal Peripheral Artery Disease: A Meta-analysis - 2 year(s) ago
If you don’t remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your passwordIf the address matches a valid account an email will be sent to __email__ with instructions for resetting your password …
Source: www.jscai.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
.@sahilparikhmd, @KhalidHamidC, @SJcardio, @JunLiMD, @MacAnsari, and Rajesh Gupta discuss the effectiveness of #DES for infrapopliteal #PAD #PADawarenessMonth 🎥➡️ https://t.co/7fztoXdaC6 https://t.co/NLYe45QLVv
-
@DAICeditor @BIOTRONIK_US A subgroup analysis of the #HOST_IDEA randomized controlled trial showed efficacy differences of #Ultrathin #Strut #DES: https://t.co/V7hsXypaKl